- Calliditas Therapeutics AB (NASDAQ:CALT) says that the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) can be expected in Q2 of 2022.
- In its review of the marketing authorization application (MAA) for Nefecon, the CHMP has informed us that they will issue an additional list of questions related to manufacturing-related information, resulting in EMA's opinion slipping into Q2.
- The continued review does not relate to the safety or efficacy of Nefecon, and there are no plans for an oral explanation.
- Related: Calliditas Shares Rally After FDA's Accelerated Approval For Budesonide For Kidney Disease.
- "Targeting an opinion in Q1 was ambitious in light of the fact that this is the first time the EMA has reviewed a drug for this indication," said CEO Renée Aguiar-Lucander.
- Price Action: CALT shares are down 5.44% at $17.90 during the market session on the last check Tuesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Calliditas Expects EMA's CHMP Opinion For Nefecon In Q2
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks